Entera Bio (ENTX) Current Deferred Revenue (2018 - 2021)

Entera Bio (ENTX) has reported Current Deferred Revenue for 4 consecutive years, with $15000.0 the latest figure, recorded in Q4 2021.

• Quarterly Current Deferred Revenue fell 90.51% year-over-year to $15000.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $15000.0 (down 90.51% YoY) and the FY2021 annual result came in at $15000.0, down 90.51% from the prior year.
• Current Deferred Revenue climbed to $15000.0 in Q4 2021 per ENTX's latest filing, from $8000.0 in the prior quarter.
• Over the last five years, Current Deferred Revenue for ENTX reached as high as $267000.0 in Q4 2019 and fell as low as $8000.0 in Q2 2021.
• A 4-year average of $141000.0 and a median of $165500.0 in 2020 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2019 — Current Deferred Revenue grew 18.67% — and 2021, when it sank 95.38%.
• Year by year, Current Deferred Revenue stood at $225000.0 in 2018, then grew by 18.67% to $267000.0 in 2019, then slumped by 40.82% to $158000.0 in 2020, then tumbled by 90.51% to $15000.0 in 2021.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $15000.0, $8000.0, and $158000.0 for Q4 2021, Q2 2021, and Q4 2020 respectively.